Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and thank you for standing by. My name is Abby and I will be your conference operator today. At this time, I would like to welcome everyone to the Sky Bioscience 2025 fourth quarter financial results and business update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one a second time. Before we begin, please note that today's discussion includes forward-looking statements subject to risks and uncertainties described in Sky's SEC filings. Actual results may differ materially. Thank you. And I would now like to turn the conference over to Puneet Dhillon, Chief Executive Officer. You may begin. Good afternoon, everyone. Thank you for joining us. I'll start with what we've accomplished since our Q3 update. C-Beyond established a potential path for namazumab alongside existing incretin therapies with additive weight loss, encouraging durability and favorable tolerability. At the same time, we strengthened the plan around the signal with 52-week combination data and a clear high-dose rationale, as well as a feasible cutaneous or subcutaneous path for delivery. And we've continued to work on the regulatory alignment and target product profile. In short, we've moved from a promising signal to a more coherent development case. And that is the backdrop for the next question. What has objectively changed over the last two years? Since launching namazumab into an obesity first indication, we've delivered a series of firsts for the CB1 field. A first-in-class allosteric GPCR antibody desi...